Cyltezois a biosimilar of AbbVie'sHumira(adalimumab).Cyltezois administered by subcutaneous injection (40 mg/0.8 mL). This is the second FDA-approved biosimilar to Humira; adalimumab-atto (Amjevita, Amgen, Inc) was the first, approved in September 2016, asreportedbyMedscape Medical News. Cyl...